Ant Group Achieves 2022 Carbon Neutrality Across Its Operations for the Second Consecutive Year
According to figures certified by the China Environmental United Certification Center (“CEC”), Ant Group has once again achieved operational carbon neutrality (Scope 1 & 2) for the second consecutive year, following the company’s initial achievement in 2021. This marks another concrete step for Ant Group towards fulfilling its pledge made in March 2021 to achieve net zero carbon emissions across Scope 1, 2 & 3 by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006073/en/
Through a combination of reduction, substitution and offset measures, Ant Group achieved carbon neutrality in Scope 1 & 2 in 2022. (Graphic: Business Wire)
The Greenhouse Gas Protocol (“Protocol”) classifies a company's Greenhouse Gas Emissions (“GHG”) into Scope 1, 2 and 3. Based on the Protocol, Ant Group, in its Carbon Neutrality Road Map, released in April 2021 , defined its GHG emissions scopes as follows:
- Scope 1: direct & fugitive emissions from the combustion of fossil fuel by the company’s owned or controlled sources.
- Scope 2: indirect emissions from the consumption of purchased energy, such as heating or cooling networks.
- Scope 3: indirect emissions which occur in the company's value chain, such as emissions from the use of leased data centers, employees’ business travel and their daily commute.
According to CEC certified figures, in 2022, after reductions and substitutions, Ant Group's greenhouse gas (GHG) emissions for Scope 1 & 2 totaled 21,087.93 tonnes of CO2e, which were fully offset by the company’s purchase of carbon credits from a Verified Carbon Standard (VCS) Project, namely the CECIC Gansu Yumen Changma No.3 Wind Farm Project (VCS Project No.728).
CEC certified figures indicate that Ant Group reduced a total of 68,665.35 tonnes of CO2e across Scope 1, 2 & 3 in 2022, up 81% from 37,909.87 tonnes in 2021. This is equivalent to taking more than 28,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2e per kilometer. The CEC was an official service provider to the 2022 Winter Olympics, helping the Olympic Committee measure the effectiveness of its carbon reduction efforts.
This reduction was mainly due to the implementation of green computing technologies. These technologies reduced about 62,000 tonnes of CO2e, which accounted for more than 99% of all carbon emissions reduced in Scope 3 during 2022. This was a 110% improvement over the 30,000 tonnes of CO2e that green computing technologies reduced in 2021.
“At Ant Group, we believe a company’s commercial value creation should go hand in hand with social value creation,“ said Yijie Peng, Chief Sustainability Officer of Ant Group. “Technological innovations has always been an important pathway for us to achieve this goal. We are committed to reaching net zero carbon emissions by 2030 and will continue to explore innovative ways to help reduce our carbon footprint and that of the industry.”
Ant Group has been developing and adopting green computing technologies since 2019. These technologies include Green AI, a series of technologies such as elastic management, GPU memory pooling and virtualization, which make large-scale model training more efficient.
For example, ATorch, Ant Group's PyTorch extension library, can double the utilization rate of AI computing power in large GPU cluster configurations compared to Megatron-DeepSpeed, an opensource deep learning optimization software suite. The use of ATorch has led to energy efficiency gains and carbon emission reductions for AI model training operations, which the company uses to iterate its AI-based products and services for better customer experience.
Ant Group also uses other green computing technologies, such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling, and OceanBase enterprise-level distributed relational database to help improve energy efficiency of data centers.
In 2022, Ant Group joined the Low Carbon Patent Pledge and granted free patent access to its green computing technologies.
The CEC’s carbon neutrality certificate for Ant Group for the year 2022 is publicly available on the Information Platform for Carbon Neutrality, which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006073/en/
Contact information
Media Enquiries
Zhumei WANG
zhumei.wzm@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom